WARNER/2014-12-02/Defs' Expert Report/6368

Total Page:16

File Type:pdf, Size:1020Kb

WARNER/2014-12-02/Defs' Expert Report/6368 December 2, 2014 Mr. John D. Hadden Assistant Attorney General Litigation Division Office of the Attorney General 313 North East 21st Street Oklahoma City, OK 73105 Re: Charles F. Warner, et al, v. Gross, et al, No CIV-14-665F Dear Mr. Hadden: I have been requested to address the pharmacological effects of the drugs used in the execution protocol for the State of Oklahoma. The following outlines the classification of the drugs in the protocol, their mechanisms of action, dosing in therapeutic use and the consequences of toxic doses as outlined in AttachmentAttachment D1, Charts A-D. 1) Midazolam Midazolam is a short acting benzodiazepine which is use as a pre-anesthetic agent for routine medical procedures to allay patient apprehension, create amnesia, and anesthesia induction. It produces different levels of central nervous system (CNS) depression through binding to gamma-aminobutyric acid (GABA) receptors. It is available in an injectable dosage form. Once the drug is administered the onset of action is 1.5-5 minutes. It is widely distributed after administration and crosses the blood brain barrier. Maximum effects are seen in 20-60 minutes with recovery occurring in 2-6 hours. Serious adverse events include cardiac arrest, agitation, apnea and respiratory depression/arrest. The drug can result in depression of the spinal reflexes and reticular activating system leading to coma and respiratory arrest. The drug will potentiate the effect of other central nervous system depressants, such as ethanol, opioids and sedative hypnotics. When given together with opioids, the dose of both drugs can be reduced. The therapeutic dose as a pre-anesthetic for adults is 1.5 – 3.5 mg for a 70kg adult less than sixty years old with a maximum recommended dose of 5mg intravenously. The maximum daily dose should not exceed 10mg. When the drug is used for induction of anesthesia no more the 40 mg. should be used. Fatalities have occurred from midazolam in doses ranging from 0.04 to 0.07mg/kg. (2.8 – 4.9mg/70Kg adult) The dose indicated in Charts C & D of Attachment D of the State of Oklahoma’s execution protocol is 500 mg IV. This dose is at least 100 times the normal therapeutic dose. When the drug is administered rapidly in this large dose it will lead to toxicity resulting in CNS depression, respiratory and cardiac arrest. Midazolam is not an analgesic however the dose administered per Chart B will render the person unconscious and ”insensate” during the remainder of the procedure. The lowest dose resulting in human deaths according the manufacturer’s “material Safety Data Sheet” is .071 mg/kg, intravenously. Over 80 deaths from the use of midazolam had occurred as of 2009. 1 Attachment D in this report refers generally to the attachment to the Oklahoma Department of Corrections execution protocol identified as OP-040301 with an effective date of 9/30/2014 that identifies specifics regarding the preparation and administration of chemicals for use in the execution of offenders sentenced to death. t^okboLOMNQJNOJMOLaÉÑëD=bñéÉêí=oÉéçêíLSPSU 2) Pentobarbital Chart A of Attachment D calls for the use of pentobarbital. This drug is a short-acting oral or parenteral barbiturate having sedative-hypnotic and anticonvulsant properties. In general, the drug has a nonselective depressant effect throughout the central nervous system due to a decrease in both pre- and postsynaptic excitability. The sedative-hypnotic effects of pentobarbital are related to its inhibition of ascending conduction in the reticular formation, which controls central nervous system arousal. The inhibition depresses the sensory cortex: decreases motor activity; alters cerebral function; and increases the threshold for electrical stimulation, which contributes to its anticonvulsant properties. It has been suggested that the sedative-hypnotic and anticonvulsant effects of barbiturates may be due to their ability to mimic the inhibitory synaptic action of gamma-aminobutyric acid. Historically, the drug was used to induce a coma characterized by absent brainstem reflexes and suppression of the EEG for patients with status epilepticus, acute eclampsia or poisoning. In order to use the drug this way, patients had to be mechanically ventilated first and a loading dose of 10-15 mg/kg IV for 1 hour with the maximum loading dose of 30mg/kg would be used. The onset of action of pentobarbital is about 1 minute following intravenous dosage. Therapeutically the drug should not be administered at rate higher than 50 mg/minute with at total dose 200-500mg. Chart A calls for 5,000 mg to be administered in an IV bolus (as rapidly as possible). Adverse Drug Reactions (selected): Apnea, respiratory depression, hypoventilation, bronchospasm, hypotension, sinus tachycardia, syncope and vasodilatation leading to cardio-pulmonary collapse may occur with rapid intravenous (IV) administration of pentobarbital. When the drug is administered in accordance with Chart A it will lead to toxicity resulting in cardio- pulmonary collapse. 3) Sodium Thiopental (Pentothal®) Chart B of Attachment D of the State of Oklahoma’s execution protocol calls for the use of sodium thiopental. Thiopental is used to induce general anesthesia prior to administration of other anesthetic agents or as the sole anesthetic agent for short surgical procedures. It is a barbiturate which had dose related hypnotic effects ranging from light sleep to unconsciousness and anterograde amnesia but no analgesia. Thiopental works by enhancing GABA activity by altering inhibitory synaptic transmissions mediated by GABAa. Onset of activity occurs in 10-40 seconds with maximal effects occurring in about one minute. The duration of action is 5-8 minutes after a single dose. This can be extended with continuous IV administration. Doses required to induce and maintain anesthesia are 50-75mg (2-3 m Lof a 2.5% solution) administered every 20-40 seconds with additional drug administered should the patient’s anesthesia lighten. Alternatively, anesthesia could be rapidly inducted with a bolus dose of 210-280 mg (3-4 mg/kg) given in 2-4 divided doses in an average 70 kg adult. Thiopental could induce respiratory depression leading to decreased ventilator response to carbon dioxide. Myocardial depression could occur resulting in arrhythmias, increased heart rate, circulatory depression and death. Oklahoma’s execution protocol Attachment D Chart B calls for 5 grams to be injected all at once which is over 20 times the dose for rapid induction which is given in divided doses. At this dose and rate of injection cardio-pulmonary arrest will occur. t^okboLOMNQJNOJMOLaÉÑëD=bñéÉêí=oÉéçêíLSPSV 4) Hydromorphone Chart C of Oklahoma’s execution protocol calls for the use of Hydromorphone Hydrochloride (Dilaudid®). The drug is an opioid agonist. It is a semisynthetic analog of morphine used to relieve severe pain in in cancer, surgery, trauma, burn, and cardiac patients. Fatal cases of respiratory arrest have occurred even when the drug was used as recommended and not misused or abused. The FDA has required a “black box warning” concerning the dangers of the drug regarding fatalities secondary to the drug’s use to be included in the manufacturer’s package insert. It is a potent mu (OP3) receptor agonist. Mu receptors couple with G-protein receptors and function as modulators, both positive and negative, of synaptic transmission via G-proteins that activate effector proteins. Analgesia is mediated through changes in the perception of pain at the spinal cord and in the central nervous system. Opioids close N-type voltage-operated calcium channels and open calcium dependent inwardly rectifying potassium channels resulting in hyperpolarization and reducing neuronal excitability. Opiates do not alter afferent nerve stimulation secondary to noxious stimuli. They do however blunt the emotional response to pain. Clinically, stimulation of mu receptors produces analgesia, respiratory depression, miosis, decreased gastrointestinal motility, and physical dependence. Respiratory depression is caused by direct action on the respiratory centers of in the brain stem. A reduction in the responsiveness of the brain stem to carbon dioxide and electrical stimulation occurs. Since the respiratory center is severely depressed at high doses of hydromorphone, it does not respond to increasing levels of carbon dioxide and therefore, there is no urge to breathe (no “air hunger”). In clinical use, 0.2 to 1 mg IV may be administered over at least 2-3 minutes every 2-3 hours as needed for pain. In the opiate naïve patient, the dose is initiated at the lowest possible amount and titrated upwards to obtain pain control. With appropriate titration there is no maximum dose. Duration of action is 4-5 hours. Intravenous administration drug distribution has two half-lives with the initial half-life being 1.27 minutes followed by 14.7 minutes. The first half-life is the time to reach equilibrium in the plasma and the second half represents the distribution to other tissues. Drug elimination is through hepatic and renal mechanism; therefore the dose would be reduced for patients with diminished hepatic or kidney function. The primary metabolite of hydromorphone is hydromorphone-3-glucuronide which has 35-40 times greater exposure than parent compound. The time it takes to eliminate half of an administered dose is 2.3 hours. These properties indicate that the drug has a very quick onset of action with its peak pharmacological effect occurring within 15 minutes. The majority of the drugs effect is seen quickly after administration via the intravenous route. At therapeutic doses, cardiovascular adverse effects include: sinus bradycardia (<2%), sinus tachycardia (<2%), palpitations (<2%), hypertension, hypotension, orthostatic hypotension, faintness, flushing, extrasystoles (<2%), and syncope. In cases of severe respiratory and/or circulatory depression, shock and cardiac arrest may occur. t^okboLOMNQJNOJMOLaÉÑëD=bñéÉêí=oÉéçêíLSPTM An overdose causes respiratory depression, extreme somnolence, stupor or coma, skeletal muscle flaccidity, cold and clammy skin, bradycardia, hypotension apnea, circulatory collapse, cardiac arrest and death.
Recommended publications
  • AMIFOSTINE for INJECTION Incidence of Grade 2 Or Higher Xerostomia (RTOG Criteria)
    TABLE 4 AMIFOSTINE FOR INJECTION Incidence of Grade 2 or Higher Xerostomia (RTOG criteria) Amifostine for RT p-value only Injection +RT LBL-7062PD Acute DESCRIPTION 51% (75/148) 78% (120/153) p<0.0001 ( 90 days from Amifostine for Injection is an organic thiophosphate cytoprotective agent known chemically ɖ start of radiation) as 2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate (ester) and has the following structural formula: Latea 35% (36/103) 57% (63/111) p=0.0016 (9-12 months H2N(CH2)3NH(CH2)2S-PO3H2 post radiation) Amifostine is a white crystalline powder which is freely soluble in water. Its empirical aBased on the number of patients for whom actual data were available. formula is C5H15N2O3PS and it has a molecular weight of 214.22. Amifostine for Injection is the trihydrate form of amifostine and is supplied as a sterile At one year following radiation, whole saliva collection following radiation showed that lyophilized powder requiring reconstitution for intravenous infusion. Each single-use 10 mL more patients given Amifostine for Injection produced >0.1 gm of saliva (72% vs. 49%). vial contains 500 mg of amifostine on the anhydrous basis. In addition, the median saliva production at one year was higher in those patients who CLINICAL PHARMACOLOGY received amifostine (0.26 gm vs. 0.1 gm). Stimulated saliva collections did not show Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a a difference between treatment arms. These improvements in saliva production were pharmacologically active free thiol metabolite. This metabolite is believed to be responsible supported by the patients’ subjective responses to a questionnaire regarding oral dryness.
    [Show full text]
  • Amifostine Is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery Or Matter-Of-Fact?
    Ha SS, Rubaina K, Lee CS, John V, Seetharamu N. Amifostine is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery or Matter-of-Fact?. J Nephrol Sci.2021;3(1):4-8 Review Article Open Access Amifostine is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery or Matter-of-Fact? Sin Sil Ha1, Kazi Rubaina1, Chung-Shien Lee1,2, Veena John2, Nagashree Seetharamu2* 1St. John’s University, College of Pharmacy and Health Sciences, Department of Clinical Health Professions, 8000 Utopia Parkway, Queens, NY 11439, USA. 2Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, 450 Lakeville Road, Lake Success, NY 11042, USA. Article Info Abstract Article Notes Despite reports of amifostine possibly protecting nephrotoxicity from Received: December 22, 2020 cisplatin, it has not been recommended by any guidelines committees or Accepted: February 01, 2021 routinely prescribed in clinical practice over the past decade. In this article, *Correspondence: we review literature and guidelines regarding use of amifostine in oncology *Dr. Nagashree Seetharamu, Division of Medical Oncology practice for protection against adverse effects from certain chemotherapeutic and Hematology, Northwell Health Cancer Institute, Donald agents, in particular as a nephro-protectant in patients receiving cisplatin. & Barbara Zucker School of Medicine at Hofstra/Northwell, 450 Lakeville Road, Lake Success, NY 11042, USA; Email: [email protected]. Background Information ©2021 Seetharamu N. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License. Amifostine (Ethyol) is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free Keywords thiol metabolite.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies
    antioxidants Review Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies 1, 2, 3 3 Andrea Gaetano Allegra y, Federica Mannino y, Vanessa Innao , Caterina Musolino and Alessandro Allegra 3,* 1 Radiation Oncology Unit, Department of Biomedical, Experimental, and Clinical Sciences “Mario Serio”, Azienda Ospedaliero-Universitaria Careggi, University of Florence, 50100 Florence, Italy; [email protected] 2 Department of Clinical and Experimental Medicine, University of Messina, c/o AOU Policlinico G. Martino, Via C. Valeria Gazzi, 98125 Messina, Italy; [email protected] 3 Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, Division of Haematology, University of Messina, 98125 Messina, Italy; [email protected] (V.I.); [email protected] (C.M.) * Correspondence: [email protected]; Tel.: +39-090-221-2364 These authors contributed equally. y Received: 15 October 2020; Accepted: 10 November 2020; Published: 12 November 2020 Abstract: Radiation therapy plays a critical role in the management of a wide range of hematologic malignancies. It is well known that the post-irradiation damages both in the bone marrow and in other organs are the main causes of post-irradiation morbidity and mortality. Tumor control without producing extensive damage to the surrounding normal cells, through the use of radioprotectors, is of special clinical relevance in radiotherapy. An increasing amount of data is helping to clarify the role of oxidative stress in toxicity and therapy response. Radioprotective agents are substances that moderate the oxidative effects of radiation on healthy normal tissues while preserving the sensitivity to radiation damage in tumor cells. As well as the substances capable of carrying out a protective action against the oxidative damage caused by radiotherapy, other substances have been identified as possible enhancers of the radiotherapy and cytotoxic activity via an oxidative effect.
    [Show full text]
  • Meta Analysis of Amifostine in 5Adiothe5apy
    0$$57 0HWD$QDO\VLVRI$PLIRVWLQH RVWLQH&LQKH5PDRGWLKRH7UKDHSU\DS\ 0(7$$1$/<6,6 2) $0,)267,1( ,1 5$',27+(5$3< ,QLWLDWHGE\WKH*URXSHG¶2QFRORJLH5DGLRWKpUDSLH7rWHHW&RX *257(& DQG,QVWLWXW*XVWDYH5RXVV\ 9LOOHMXLI)UDQFH 3URWRFRO -XQH 6(&5(7$5,$7 &OLQLFDO&RRUGLQDWRU Jean Bourhis, MD, PhD Départment de Radiothérapie Institut Gustave Roussy Rue Camille Desmoulins 94 805 Villejuif Cédex FRANCE Tel : 33 1 42 11 49 98 Fax : 33 1 42 11 52 99 e-mail : [email protected] 6WDWLVWLFLDQ Jean-Pierre Pignon, MD, PhD e-mail : [email protected] &OLQLFDO0DQDJHU Kullathorn Thephamongkhol, MD, MSc e-mail: [email protected] 6HFUHWDU\ Denise Avenell e-mail : [email protected] $GPLQLVWUDWLYHDGGUHVV : MAART Secretariat c/o Department of Biostatistics Institut Gustave Roussy 39, rue Camille Desmoulins 94 805 Villejuif Cédex FRANCE 7(/ )$; &217(176 PAGE INTRODUCTION ................................................................................ 1 OBJECTIVES ....................................................................................... 2 TRIAL SELECTION CRITERIA ........................................................ 3 TRIAL SEARCH.................................................................................. 3 DESCRIPTION OF INCLUDED TRIALS .......................................... 4 CRITERIA OF EVALUATION ........................................................... 4 DATA COLLLECTION AND QUALITY CONTROL....................... 5 STATISTICAL ANALYSIS PLAN ..................................................... 6 WORKING PARTIES IN THE META-ANALYSIS..........................
    [Show full text]
  • 2000 Dialysis of Drugs
    2000 Dialysis of Drugs PROVIDED AS AN EDUCATIONAL SERVICE BY AMGEN INC. I 2000 DIAL Dialysis of Drugs YSIS OF DRUGS Curtis A. Johnson, PharmD Member, Board of Directors Nephrology Pharmacy Associates Ann Arbor, Michigan and Professor of Pharmacy and Medicine University of Wisconsin-Madison Madison, Wisconsin William D. Simmons, RPh Senior Clinical Pharmacist Department of Pharmacy University of Wisconsin Hospital and Clinics Madison, Wisconsin SEE DISCLAIMER REGARDING USE OF THIS POCKET BOOK DISCLAIMER—These Dialysis of Drugs guidelines are offered as a general summary of information for pharmacists and other medical professionals. Inappropriate administration of drugs may involve serious medical risks to the patient which can only be identified by medical professionals. Depending on the circumstances, the risks can be serious and can include severe injury, including death. These guidelines cannot identify medical risks specific to an individual patient or recommend patient treatment. These guidelines are not to be used as a substitute for professional training. The absence of typographical errors is not guaranteed. Use of these guidelines indicates acknowledgement that neither Nephrology Pharmacy Associates, Inc. nor Amgen Inc. will be responsible for any loss or injury, including death, sustained in connection with or as a result of the use of these guidelines. Readers should consult the complete information available in the package insert for each agent indicated before prescribing medications. Guides such as this one can only draw from information available as of the date of publication. Neither Nephrology Pharmacy Associates, Inc. nor Amgen Inc. is under any obligation to update information contained herein. Future medical advances or product information may affect or change the information provided.
    [Show full text]
  • Package Leaflet: Information for the Patient Olmesartan Medoxomil/Hydrochlorothiazide 20 Mg/12.5 Mg Film-Coated Tablets Olmesart
    Package leaflet: Information for the patient Olmesartan medoxomil/Hydrochlorothiazide 20 mg/12.5 mg Film-coated Tablets Olmesartan medoxomil/Hydrochlorothiazide 20 mg/25 mg Film-coated Tablets (olmesartan medoxomil and hydrochlorothiazide) Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Olmesartan medoxomil/Hydrochlorothiazide is and what it is used for 2. What you need to know before you take Olmesartan medoxomil/Hydrochlorothiazide 3. How to take Olmesartan medoxomil/Hydrochlorothiazide 4. Possible side effects 5. How to store Olmesartan medoxomil/Hydrochlorothiazide 6. Contents of the pack and other information 1. What Olmesartan medoxomil/Hydrochlorothiazide is and what it is used for Olmesartan medoxomil/Hydrochlorothiazide contains two active substances, olmesartan medoxomil and hydrochlorothiazide, that are used to treat high blood pressure (hypertension): Olmesartan medoxomil is one of a group of medicines called angiotensin II-receptor antagonists. It lowers blood pressure by relaxing the blood vessels. Hydrochlorothiazide is one of a group of medicines called thiazide diuretics (“water tablets”). It lowers blood pressure by helping the body to get rid of extra fluid by making your kidneys produce more urine.
    [Show full text]
  • ETHYOL® (Amifostine)
    1 ETHYOLâ (amifostine) for Injection RX only 2 3 DESCRIPTION 4 5 ETHYOL (amifostine) is an organic thiophosphate cytoprotective agent known chemically as 2-[(3- 6 aminopropyl)amino]ethanethiol dihydrogen phosphate (ester) and has the following structural 7 formula: 8 9 H2N(CH2)3NH(CH2)2S-PO3H2 10 11 Amifostine is a white crystalline powder which is freely soluble in water. Its empirical formula is 12 C5H15N2O3PS and it has a molecular weight of 214.22. 13 14 ETHYOL is the trihydrate form of amifostine and is supplied as a sterile lyophilized powder 15 requiring reconstitution for intravenous infusion. Each single-use 10 mL vial contains 500 mg of 16 amifostine on the anhydrous basis. 17 18 CLINICAL PHARMACOLOGY 19 20 ETHYOL is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a 21 pharmacologically active free thiol metabolite. This metabolite is believed to be responsible for the 22 reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of 23 radiation on normal oral tissues. The ability of ETHYOL to differentially protect normal tissues is 24 attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of 25 normal tissues relative to tumor tissue, which results in a more rapid generation of the active thiol 26 metabolite as well as a higher rate constant for uptake into cells. The higher concentration of the 27 thiol metabolite in normal tissues is available to bind to, and thereby detoxify, reactive metabolites 28 of cisplatin. This thiol metabolite can also scavenge reactive oxygen species generated by exposure 29 to either cisplatin or radiation.
    [Show full text]
  • The Efficacy of Amifostine Against Multiple-Dose Doxorubicin-Induced Toxicity in Rats
    International Journal of Molecular Sciences Article The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats Vesna Ja´cevi´c 1,2,3 ID , Viktorija Dragojevi´c-Simi´c 2,4, Željka Tatomirovi´c 2,5, Silva Dobri´c 2,6 ID , Dubravko Bokonji´c 2, Aleksandra Kovaˇcevi´c 2,4, Eugenie Nepovimova 3, Martin Vališ 7 and Kamil Kuˇca 3,* ID 1 Department of Experimental Toxicology and Pharmacology, National Poison Control Centre, Military Medical Academy, 11 Crnotravska St, 11000 Belgrade, Serbia; [email protected] 2 Medical Faculty of the Military Medical Academy, University of Defense in Belgrade, 1 Pavla Juriši´ca-Šturma St, 11000 Belgrade, Serbia; [email protected] (V.D.-S.); [email protected] (Ž.T.); [email protected] (S.D.); [email protected] (D.B.); [email protected] (A.K.) 3 Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanského 62, 50003 Hradec Králové, Czech Republic; [email protected] 4 Centre for Clinical Pharmacology, Military Medical Academy, 11 Crnotravska St, 11000 Belgrade, Serbia 5 Institute for Pathology, Military Medical Academy, 11 Crnotravska St, 11000 Belgrade, Serbia 6 Institute for Scientific Information, University of Defense in Belgrade, 1 Pavla Juriši´ca-ŠturmaSt, 11000 Belgrade, Serbia 7 Department of Neurology, Charles University in Prague, Faculty of Medicine in Hradec Kralove and University Hospital, Simkova 870, 50003 Hradec Králové, Czech Republic; [email protected] * Correspondence: [email protected]; Tel.: +420-603-289-166 Received: 30 June 2018; Accepted: 7 August 2018; Published: 12 August 2018 Abstract: Amifostine is well known cytoprotector which is efficient when administered before a wide range of antineoplastic agents.
    [Show full text]
  • Prebiotic Synthesis of Methionine and Other Sulfur-Containing Organic Compounds on the Primitive Earth: a Contemporary Reassessm
    PREBIOTIC SYNTHESIS OF METHIONINE AND OTHER SULFUR-CONTAINING ORGANIC COMPOUNDS ON THE PRIMITIVE EARTH: A CONTEMPORARY REASSESSMENT BASED ON AN UNPUBLISHED 1958 STANLEY MILLER EXPERIMENT Eric T. ParkerL*, H. James Cleaves2, Michael P. Callahan, Jason P. Dworkin 3, Daniel P. Glavin, Antonia Lazcanoa, and Jeffrey L. Badal Scripps Institution of Oceanography, University of California at San Diego, La Jolla, CA 92093, ; A5. 'Geophysical Laboratory, Carnegie Institution of Washington, 5251. Broad Branch Rd. NW, "Washington, DC 20015, USA; 3'LTASA Goddard Space flight Center, Solar System Exploration Division, Greenbelt, MD 20771, USA; 4Facultad de Ciencias, UNAM, Apdo. Postal 74-447 Cd. Universitaria, 04510 Mexico D. F., Mexico Address correspondence to: Jeffrey L. Bada, Scripps Institution of Oceanography, University of California at San Diego, 8615 Kennel Way, La Jolla, CA 92093-0212, USA; phone: 858 534- 4258; fax: 858 534-2995; email; jb d < cscl.c i * Present address, School of Earth & Atmospheric Sciences, Georgia Institute of Technology,. Atlanta, GA 34332, USA ABSTRACT Original extracts from an unpublished 1958 experiment conducted by the late Stanley L. Miller were recently found and analyzed using modern state-of-the-art analytical methods. The extracts were produced by the action of an electric discharge on a mixture of methane (CU4), hydrogen sulfide (H2S), ammonia (NH3), and carbon dioxide (CO2). Racemic methionine was farmed in significant yields, together with other sulfur-bearing organic compounds. The formation of methionine and other compounds from a model prebiotic atmosphere that contained H2S suggests that this type of synthesis is robust under reducing conditions, which may have existed either in the global primitive atmosphere or in localized volcanic environments on the early Earth.
    [Show full text]
  • Identification of a Transaminative Pathway for Ethionine Catabolism1
    [CANCER RESEARCH 39, 3935-3941, October 1979] 0008-54 72/79 /0039-OOOOS02.00 Identification of a Transaminative Pathway for Ethionine Catabolism1 Robert D. Steele2 and Norlin J. Benevenga3 Departments of Nutritional Sciences and Meat and Animal Science, University of Wisconsin, Madison, Wisconsin 53706 ABSTRACT extensively in recent years in an effort to explain why methio nine is the most toxic of the dietary amino acids (19). Studies The potential for the oxidation of ethionine by a transamina- by Benevenga et al. (7-9, 26) showed that a pathway for tive route was studied in an attempt to elucidate the pathways methionine oxidation independent of S-adenosylmethionine whereby the ethyl carbons of ethionine are converted to carbon formation was operative and that formaldehyde and formate dioxide. Ethionine is transaminated based on the recovery of were 2 intermediates in the oxidation of the methionine methyl a radioactive phenylhydrazone derivative. Carbon 1 of the ethyl group. It has since been shown that a transaminative pathway portion of ethionine is recovered as carbon dioxide when L- [ef/jy/-1-14C]ethionine is incubated in a rat liver homogenate of methionine catabolism represented a major part of the catabolism of methionine in liver homogenate preparations of system. The addition of pyruvate as an amino group acceptor rats and monkeys (27, 37). Methionine was shown to be for transamination stimulated oxidation by more than 10-fold transaminated to its keto acid, a-keto-y-methiolbutyrate, and based on carbon dioxide formation and on recovery of the a- then decarboxylated to 3-methylthiopropionate (37). Rats fed keto acid of ethionine as the phenylhydrazone derivative.
    [Show full text]
  • Nephroprotection by Theophylline in Patients with Cisplatin Chemotherapy: a Randomized, Single-Blinded, Placebo-Controlled Trial
    JASN Express. Published on December 8, 2004 as doi: 10.1681/ASN.2004030225 Nephroprotection by Theophylline in Patients with Cisplatin Chemotherapy: A Randomized, Single-Blinded, Placebo-Controlled Trial Peter Benoehr,* Patricia Krueth,† Carsten Bokemeyer,† Almut Grenz,‡ Hartmut Osswald,‡ and Jorg T. Hartmann† *Department of Nephrology and Rheumatology, University of Go¨ttingen, Go¨ttingen, Germany; and †Medical Center II, Department of Hematology and Oncology, Immunology, Rheumatology and Pneumonology and ‡Department of Pharmacology and Toxicology, Eberhard-Karls University of Tu¨bingen, Tu¨bingen, Germany The aim of the present study was to assess the possible prevention of cisplatin-induced impairment of GFR by theophylline in patients with various malignancies. The trial design was parallel, randomized, single blinded, and placebo controlled. Patients received cisplatin at a dosage of 50 mg/m2 either combined with etoposide, ifosfamide, and epirubicin or with paclitaxel and 5-fluorouracil/folinic acid with the usual precautions, including a standard hydration scheme before application of cisplatin in both arms. In the control arm, placebo was administered; in the verum arm, patients received theophylline in a loading dose of 4 mg/kg intravenously over 30 min before cisplatin, followed by 0.4 mg/kg per min over a minimum of 6 h, and then 350 mg three times daily orally for 4 consecutive days after completion of chemotherapy. GFR of each patient was assessed by renal clearance of inulin within 3 d before and at day 5 after cisplatin chemotherapy. Despite usual precautions, patients in the placebo group had a 21% decrease (range, 11 to 31%) of inulin clearance after a single cycle of cisplatin- containing chemotherapy (92.9 ؎ 3.4 versus 71.8 ؎ 3.5 ml/min; P < 0.01).
    [Show full text]